Loss of Smad4 Function in Pancreatic Tumors
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
At early stages of tumorigenesis, the transforming growth factor-beta (TGF-beta) signaling pathway is thought to have tumor suppressor activity as a result of its ability to arrest the growth of epithelial cells. Smad4 plays a pivotal role in the TGF-beta signaling pathway and has been identified as a tumor suppressor, being mutated or deleted in approximately 50% of pancreatic carcinomas and 15% of colorectal cancers. A nonsense mutation generating a C-terminal truncation of 38 amino acids in the Smad4 protein has been identified in a pancreatic adenocarcinoma (Hahn, S. A., Schutte, M., Hoque, A. T., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., and Kern, S. E. (1996) Science 271, 350-353), and here we investigate the functional consequences of this mutation. We demonstrate that the C-terminal truncation prevents Smad4 homomeric complex formation and heteromeric complex formation with activated Smad2. Furthermore, the mutant protein is unable to be recruited to DNA by transcription factors and hence cannot form transcriptionally active DNA-binding complexes. These observations are supported by molecular modeling, which indicates that the truncation removes residues critical for homomeric and heteromeric Smad complex formation. We go on to show that the mutant Smad4 is highly unstable compared with wild type Smad4 and is rapidly degraded through the ubiquitin-proteasome pathway. Consistent with this, we demonstrate that the pancreatic adenocarcinoma harboring this mutated allele, in conjunction with loss of the other allele, expresses no Smad4 protein. Thus we conclude that these tumors completely lack Smad4 activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1
Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337
Cited by
Moustakas, A., & Heldin, C.-H. (2005) · Journal of Cell Science · doi:10.1242/jcs.02554 · Cited by 958
Smad regulation in TGF-β signal transduction
Moustakas, A., Souchelnytskyi, S., & Heldin, C.-H. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.24.4359 · Cited by 929
Valcourt, U., Kowanetz, M., Niimi, H., Heldin, C.-H., & Moustakas, A. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0658 · Cited by 610
The HECT Family of E3 Ubiquitin Ligases: Multiple Players in Cancer Development
Bernassola, F., Karin, M., Ciechanover, A., & Melino, G. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.001 · Cited by 541
Alterations in components of the TGF-β superfamily signaling pathways in human cancer
LEVY, L., & HILL, C. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.09.009 · Cited by 539
“Such C-terminal truncations can also affect Smad4 protein stability [81].”
BackgroundSelf-citationActions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer
Pardali, K., & Moustakas, A. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.06.004 · Cited by 526
Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
Thomas, D., & Radhakrishnan, P. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0927-5 · Cited by 396
How the Smads regulate transcription
Ross, S., & Hill, C. S. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.09.006 · Cited by 383
Self-citationKowanetz, M., Valcourt, U., Bergström, R., Heldin, C.-H., & Moustakas, A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.10.4241-4254.2004 · Cited by 346
Levy, L., & Hill, C. S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.18.8108-8125.2005 · Cited by 342
Self-citationKRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
Cicenas, J., Kvederaviciute, K., Meskinyte, I., Meskinyte-Kausiliene, E., Skeberdyte, A., & Cicenas, J. (2017) · Cancers · doi:10.3390/cancers9050042 · Cited by 272
Regulation of the TGFβ signalling pathway by ubiquitin-mediated degradation
Izzi, L., & Attisano, L. (2004) · Oncogene · doi:10.1038/sj.onc.1207412 · Cited by 258
Lanauze, C. B., Sehgal, P., Hayer, K., Torres-Diz, M., Pippin, J. A., Grant, S. F. A., & Thomas-Tikhonenko, A. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0721 · Cited by 17
“To compare and contrast the co-occurrence frequency of CTNNB1 mutations in CRCs alongside either SMAD4 missense or loss-of-function nonsense mutations (31, 40), we utilized the chi-square test with Yate’s correction.”
BackgroundMethod
Metadata
- Authors
- Maurice, D., Pierreux, C. E., Howell, M., Wilentz, R. E., Owen, M. J., & Hill, C. S.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-11
- Volume
- 276
- Issue
- 46
- Pages
- 43175-43181
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2040982470
- Cited by
- 95
- References
- 1
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.